Biovica CEO Anders Rylander
| Published December 1, 2023

BioStock Investor Pitch: Biovica

The Uppsala company Biovica has concluded a number of agreements during the year regarding its cancer test DiviTum TKa and the launch is underway in both the USA and Europe. The purpose of DiviTum TKa is to be able to evaluate the effect of cancer treatments more quickly and better. The company is now carrying out a capital raising of initially up to SEK 120 million to finance continued market investments.

Se Biovicas vd Anders Rylander present the company below.

This advertisement has been prepared for marketing purposes and does not constitute a prospectus within the meaning of Regulation (EU) 2017/1129 of the European Parliament and of the Council (Prospectus Regulation). The full terms and conditions of the rights issue, and more information about Biovica International AB (publ), have been set out in a prospectus approved by the Swedish Financial Supervisory Authority on 28 November 2023 and published on https://biovica.com/investor-relations/rights-issue-2023/. The Swedish Financial Supervisory Authority approves the prospectus only to the extent that it meets the requirements for completeness, comprehensibility and consistency set out in the Prospectus Regulation. The approval should not be considered as any kind of endorsement of Biovica or endorsement of the quality of the securities referred to in the prospectus. The prospectus contains a description of the risks and benefits associated with an investment in Biovica and potential investors are advised to read the Prospectus in its entirety before making an investment decision.